Белорусский государственный медицинский университет, Минск, Беларусь Administration of eltrombopag in patients with HCV-associated thrombocytopenia Использование эльтромбопага у пациентов с ВГС-ассоциированной тромбоцитопенией ______________________ Abstract __________________________________________________________________________ The article describes the experience of eltrombopag administration in patients with thrombocytopenia associated with chronic viral hepatitis C / hepatic cirrhosis for achievement of platelet concentration suffi cient to initiate and continue the therapy based on pegylated interferon, and use of fi rst-generation protease inhibitors (boceprevir). <...> Keywords: eltrombopag, chronic viral hepatitis C, hepatic cirrhosis, thrombocytopenia, triple therapy, boceprevir. ______________________ Резюме __________________________________________________________________________ В статье описывается опыт применения эльтромбопага у пациентов с тромбоцитопенией, ассоциированной с хроническим вирусным гепатитом С / циррозом печени для достижения уровня тромбоцитов, достаточного для инициации и продолжения терапии на основе пегилированного интерферона, а также в схемах с использованием ингибиторов протеазы первого поколения (боцепревир). <...> Ключевые слова: эльтромбопаг, хронический вирусный гепатит С, цирроз печени, тромбоцитопения, трехкомпонентная терапия, боцепревир. _________________________________________________________________________________________________ Quite often, in patients with hepatic cirrhosis in the outcome of HCV, under pressure of an antiviral therapy with interferon, side eff ects associated with an inhibition of blood shoots: the incidence of thrombocytopenia and/or neutropenia in a systematic review reached 23.2% [1]. <...> There are publications that argue for forgoing causal treatment in patients with chronic viral hepatitis C or hepatic cirrhosis in the outcome of viral hepatitis, having a low platelet count [2]. <...> Eltrombopag is a new way of thrombocytopenia follow-up in patients with chronic HCV and hepatic cirrhosis in the outcome of a viral process [3]. <...> Eltrombopag allows to initiate a course of antiviral pegylated interferonbased therapy, as well as to continue antiviral treatment in patients with 284 "Clinical infectology and parasitology" 2016, volume 5, № 3 Оригинальные исследования thrombocytopenia, adhering to timescales required to achieve the sustained virological response. <...> Thus, eltrombopag may indirectly contribute to the elimination of HCV in patients with low platelet counts [4]. <...> However, this applies primarily to patients with a platelet count above 50*109 /L (the multivariate analysis showed that the risk of bleeding when reducing a platelet count below this level increases signifi cantly). <...> Moreover, the global <...>